[Form 4] Vivos Therapeutics, Inc. Insider Trading Activity
Vivos Therapeutics, Inc. (symbol: VVOS) is the issuer of record for a Form 4 filing submitted to the SEC.
Rhea-AI Filing Summary
Vivos Therapeutics, Inc. (symbol: VVOS) is the issuer of record for a Form 4 filing submitted to the SEC.
Positive
- None.
Negative
- None.
Insider Trade Summary
Other: 171,820 shares
Other
5 txns
Insider
Huntsman Ronald Kirk
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Warrant (Right to Buy) F2 | 85,910 | $0.582 | $50K |
| Other | Preferred Stock F2 | 85,910 | $0.582 | $50K |
| holding | Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Warrant (Right to Buy) — 85,910 contracts (Indirect, See footnote);
Preferred Stock — 85,910 shares (Indirect, See footnote);
Stock Options (Right to Buy) — 359,754 contracts (Direct);
Common Stock — 3,461 shares (Direct);
Common Stock — 69,600 shares (Indirect, See footnote)
Footnotes (3)
- F1. Shares held by Coronado V Partners, LLC, of which the Reporting Person is a member and manager.
- F2. On June 30, 2026, the Reporting Person participated in the PIPE Offering indirectly through V-Co Investors 4 LLC ("V-Co 4"), in which he acquired a membership interest. His indirect interest in V-Co 4 represents approximately $50,000 of the aggregate purchase price paid by V-Co 4, corresponding to 85,910 shares of Series A Convertible Preferred Stock and Warrants to purchase 85,910 shares of Common Stock purchased of record by V-Co 4. The securities reported are held of record by V-Co 4. The Preferred Stock is convertible at any time at the holder's election, subject to a beneficial ownership limitation, and has no expiration date. The warrants are exercisable at $0.456 per share through June 30, 2031. The $0.582 price reported is the per-unit price in the PIPE Offering. The Reporting Person disclaims beneficial ownership of the securities held by V-Co 4 except to the extent of his pecuniary interest therein.
- F3. Represents employee stock options granted on various dates, with exercise prices ranging from $2.38 to $81.75 and expiration dates ranging from February 25, 2027 to September 7, 2034, and also reflects the expiry of 5,001 stock options granted June 16, 2021 that were previously reported on the Reporting Person's Form 4 filed on November 27, 2024, which expired unexercised on June 26, 2026. Table II reports the earliest expiration dates (02/25/2027).
AI-generated analysis. How Rhea-AI works. Not financial advice.
